还原型谷胱甘肽治疗抗结核药物性肝损害的临床观察

目的探讨还原型谷胱甘肽防治抗结核药物肝损害的临床效果。方法将确诊为肺结核的患者196例，随机分为治疗组102例和对照组94例。治疗组在肺结核联合化疗的同时，全程加服还原型谷胱甘肽片（阿拓莫兰片），对照组在肺结核联合化疗的同时，加服肌苷、肝太乐等护肝药。结果治疗组出现肝损害6例（59％），其中11例HBsAg阳性患者中有1例（91％）出现肝损害；对照组出现肝损害32例（34．0％）。其中10例HBsAg阳性患者中有6例（60％）出现肝损害。两组差异有统计学意义，P〈001，HBsAg阳性患者肝功能更易受损害。结论还原型谷胱甘肽对防治抗结核药物性肝损害临床疗效确切，安全有效。

Clinical observation of reduced glutathione in treating liver injury caused by antitubercular agents

Objective To explore the clinical effects of reduced glutathione in preventing and treating liver injury caused by antitubercular agents. Methods 196 patients confirmed with pulmonary tuberculosis were randomly divided into treatment group (n=102) and control group (n=94). During the combination chemotherapy, the treatment group additionally took reduced glutathione whole couse, the control group additionally took Inosine, Glucurose. Results Six patients appeared liver damage in the treatment group (5.9%), among the eleven HBsAg positive patients, there were one case of liver damage (9.1%); thirty-two cases appeared liver damage in the control group (34.0%), among ten HBsAg positive patients, there were six cases of liver damage(60.0%). There was significant difference between the groups (P<0.01). The liver function of HBsAg positive patients were more vulnerable to damage. Conclusion The clinical effects of the reduced glutathione in preventing and treating liver injury caused by antitubercular agents is precise, safe and effective.